Sio Gene Therapies to Participate in Upcoming Investor & Scientific Conferences
- Wall Street ends week positively; S&P 500, Dow hit record highs
- Bitcoin (BTC) Drops 3% as Turkey Bans Cryptocurrency Payments Citing Lack of Regulatory Supervision
- Morgan Stanley (MS) Archegos-Related Loss Appears to be $911M
- Dollar at 4-week low on retreating Treasury yields
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
NEW YORK and RESEARCH TRIANGLE PARK, N.C., March 11, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that the company will participate in select upcoming investor and scientific conferences. Details can be found below.
|Oppenheimer 31st Annual Healthcare Conference|
|Participation:||Company presentation and 1-on-1 investor meetings|
|Presenter:||Gavin Corcoran, MD, Chief R&D Officer|
|Presentation Date & Time:||Wednesday, March 17, 2021 at 2:30 PM ET|
|Redburn Gene Therapy Virtual Summit|
|Participation:||Panel discussion: “Defining a Gene Therapy Market”|
|Presenter:||Parag V. Meswani, PharmD, Chief Commercial Officer|
|Panel Date & Time:||Wednesday, March 31, 2021 at 8:00 AM ET|
|Guggenheim Healthcare Talks: 2021 Genomic Medicines & Rare Disease Day|
|Participation:||1-on-1 investor meetings|
|Date:||Thursday, April 1, 2021|
|Gene Therapy Patient Engagement Summit|
|Date:||March 23-25, 2021|
About Sio Gene Therapies
Sio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients. Our current pipeline of clinical-stage candidates includes the first potentially curative AAV-based gene therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff diseases, which are rare and uniformly fatal pediatric conditions caused by single gene deficiencies. We are also expanding the reach of gene therapy to highly prevalent conditions such as Parkinson’s disease, which affects millions of patients globally. Led by an experienced team of gene therapy development experts, and supported by collaborations with premier academic, industry and patient advocacy organizations, Sio is focused on accelerating its candidates through clinical trials to liberate patients with debilitating diseases through the transformational power of gene therapies. For more information, visit www.siogtx.com.
Josephine Belluardo, Ph.D.
Investors and Analysts
Parag V. Meswani
Sio Gene Therapies Inc.
Chief Commercial Officer
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DOX INVESTOR ALERT: Bernstein Liebhard is Investigating Amdocs Limited For Violations of the Securities Laws
- Monument Announces RSU Grants
- DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Jianpu Technology, Inc. and Encourages Investors to Contact the Firm